← Back to patent-cliff list
Guanabenz Acetate
Tier C — Watch / tradeGuanabenz Acetate
Pfizer Inc.
Originator
1982
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Adrenoceptors
Brand：Wytensin, Wytens
Indications (approved)：Non-alcoholic steatohepatitis, Essential hypertension, Multiple sclerosis, Relapsing-remitting multiple sclerosis
Regional status
US
Withdrawn
EU
-
China
-
Japan
Phase II
2021-10-29
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Guanabenz Acetate?
Approved indications include: Non-alcoholic steatohepatitis, Essential hypertension, Multiple sclerosis, Relapsing-remitting multiple sclerosis.
When does the Guanabenz Acetate patent expire?
No public expiry year is available for Guanabenz Acetate yet; this page updates once verified.
How do I get a quote for Guanabenz Acetate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06